Solórzano SF

Language: Spanish
References: 7
Page: 129
PDF size: 101.26 Kb.

Text Extraction

no abstract

REFERENCES

1. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA et al. “Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program”. J Clin Microbiol 2004; 42: 1519-1527.

2. Stoll BJ, Hansen N, Fanaroff AA, Wright L, Carlo WA, Ehrenkranz RA et al. “Late-onset sepsis in very low birth weight neonates: the experience of the nichd Neonatal Research Network”. Pediatrics 2002; 110: 285-291.

3. Almirante B, Rodríguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J et al., del Barcelona Candidemia Project Study Group. “Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003”. J Clin Microbiol 2005; 43: 1829-1835.

4. Muller FM, Weig M, Peter J, Walsh TJ. “Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from hiv-infected children with oropharyngeal candidosis”. J Antimicrob Chemother 2000; 46: 338–340.

5. Espinel-Ingroff A “Mechanisms of resistance to antifungal agents: Yeasts and filamentous fungi”. Rev Iberoam Micol 2008; 25: 101-106.

6. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C et al. “Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents”. Antimicrob Agents Chemother 2005; 49: 4536–4545.

7. Catalán González M, Montejo González JC. “Nueva aportación en terapia antifúngica: Anidulafungina. Aspectos farmacológicos de la anidulafungina”. Rev Iberoam Micol 2008; 25: 92-100.